Document:

EX-10.27

 Exhibit 10.27 

TAX SHARING AGREEMENT 

THIS AGREEMENT is entered into by and among BridgeBio Pharma, Inc. (“BridgeBio”), [SUBSIDIARY]
(“[SUBSIDIARY]”), and each of the undersigned affiliates (the “Affiliates”, or in the singular “Affiliate”), collectively the “Parties” and each individually, a
“Party” as of [                    ]. 

WHEREAS, BridgeBio, [SUBSIDIARY], and or some or all of their respective Affiliates may join in the filing of U.S. federal, state, local or
other tax returns on a consolidated, combined or unitary basis; and 
 WHEREAS, BridgeBio intends to effect an initial public offering of
its common stock (“IPO”), and at the time of the IPO will have undergone a reorganization pursuant to which BridgeBio becomes the corporate parent of the operating companies that conduct BridgeBio’s operations; 

WHEREAS, it is desirable for BridgeBio, [SUBSIDIARY] and their respective Affiliates to enter into a tax sharing agreement (the
“Agreement”) to provide for the manner of computation and the liability for and of the amounts and timing of payments among them, and various related matters; 

NOW, THEREFORE, in consideration of the agreements contained herein and of other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereby agree as follows: 

  
 1 

 Section 1. Definitions 

As used in this Agreement, capitalized terms shall have the following meanings (such meanings to be equally applicable to both the singular and
the plural forms of the terms defined): 
 “Affiliates” has the meaning set forth in the Preamble. 

“Affiliated Group” means an affiliated group of corporations within the meaning of Section 1504(a) of the Code that files a consolidated
return for U.S. federal Income Tax purposes. 
 “After Tax Amount” means any additional amount necessary to reflect the hypothetical Tax
consequences of the receipt or accrual of any payment required to be made under this Agreement (including payment of any additional amount or amounts hereunder and the effect of the deductions available for interest paid or accrued for Taxes such as
state and local Income Taxes), determined by using the highest applicable statutory corporate Income Tax rate (or rates, in the case of an item that affects more than one Tax) for the relevant Taxable Period (or portion thereof). 

“Agreement” has the meaning set forth in the Preamble. 

“Audit” means any audit, assessment of Taxes, or other examination by any Taxing Authority, proceeding or appeal of such a proceeding
relating to Taxes, whether administrative or judicial, including proceedings relating to competent authority determinations. 
 “BridgeBio”
has the meaning set forth in the Preamble. 
 “BridgeBio Affiliate” means any corporation or other entity directly or indirectly
controlled by BridgeBio at the time in question, where controlled means the ownership of fifty percent (50%) or more of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or
indirectly, of the power to direct or cause the direction of the management or policies of such corporation or other entity, but at all times excluding [SUBSIDIARY] or any [SUBSIDIARY] Affiliate. 

“BridgeBio Business” means all of the businesses and operations conducted by BridgeBio and the BridgeBio Affiliates, excluding the
[SUBSIDIARY] Business, at any time, whether prior to or after the IPO Date. 
 “BridgeBio Group” means the Affiliated Group, or similar
group of entities as defined under corresponding provisions of the laws of any other jurisdictions, of which BridgeBio is the common parent corporation, and any corporation or other entity which may be, may have been or may become a member of such
group from time to time, but excluding any member of the [SUBSIDIARY] Group. 
 “BridgeBio Registration Statement” means the
registration statement on Form S-1, originally filed with the U.S. Securities and Exchange Commission on May 24, 2019 (File no. 333-231759), as so filed and
amended. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Combined Return” means any Tax Return with respect to Income Taxes (other than with respect to U.S. federal Income Taxes) filed on a
consolidated, combined (including nexus combination, worldwide combination, domestic combination, line of business combination or any other form of combination) or unitary basis wherein [SUBSIDIARY] or one or more [SUBSIDIARY] Affiliates join in the
filing of such Tax Return (for any Taxable Period) with BridgeBio or one or more BridgeBio Affiliates. 

  
 2 

 “Consolidated Return” means any Tax Return with respect to U.S. federal Income Taxes filed
on a consolidated basis wherein [SUBSIDIARY] or one or more [SUBSIDIARY] Affiliates join in the filing of such Tax Return (for any Taxable Period) with BridgeBio or one or more BridgeBio Affiliates. 

“Controlling Party” has the meaning set forth in Section 9.1. 

“Deconsolidation Event” means, with respect to [SUBSIDIARY] and each [SUBSIDIARY] Affiliate, any event or transaction that causes
[SUBSIDIARY] and or one or more [SUBSIDIARY] Affiliates to no longer be eligible to join with BridgeBio or one or more BridgeBio Affiliates in the filing of a Consolidated Return or a Combined Return, including, but not limited to, a Distribution.

 “Distribution” means any distribution by BridgeBio of the issued and outstanding shares of [SUBSIDIARY] common stock (and securities, if
any) that BridgeBio holds at such time to BridgeBio shareholders and or securityholders in a transaction intended to qualify under Section 355 of the Code. 

“Distribution Taxes” means any Taxes imposed on, or increase in Taxes incurred by, BridgeBio or any BridgeBio Affiliate, and any Taxes of a
BridgeBio shareholder (or former BridgeBio shareholder) that are required to be paid or reimbursed by BridgeBio or any BridgeBio Affiliate pursuant to a legal determination, provided that BridgeBio shall have defended itself in any legal proceeding
involving Taxes of a BridgeBio shareholder, (without regard to whether such Taxes are offset or reduced by any Tax Asset, Tax Item, or otherwise) resulting from, or arising in connection with, the failure of Distribution to qualify as a tax-free
transaction under Section 355 of the Code (including any Tax resulting from the application of Section 355(d) or Section 355(e) of the Code to a Distribution) or corresponding provisions of the laws of any other jurisdictions. Any
Income Tax referred to in the immediately preceding sentence shall be determined using the highest applicable statutory corporation Income Tax rate for the relevant Taxable Period. For the avoidance of doubt, Distribution Taxes shall not include any
Taxes allocated pursuant to Section 4 of this Agreement. 
 “[SUBSIDIARY]” has the meaning set forth in the Preamble. 

“[SUBSIDIARY] Affiliate” means any corporation or other entity directly or indirectly controlled by [SUBSIDIARY] at the time in
question, where controlled means the ownership of fifty percent (50%) or more of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of such corporation or other entity; but at all times excluding BridgeBio or any BridgeBio Affiliate. 

“[SUBSIDIARY] Business” means all of the businesses and operations conducted by [SUBSIDIARY] and the [SUBSIDIARY] Affiliates, excluding the
BridgeBio Business, at any time, whether prior to or after the IPO Date. 
 “[SUBSIDIARY] Group” means the Affiliated Group, or similar
group of entities as defined under corresponding provisions of the laws of any other jurisdictions, of which [SUBSIDIARY] is, or would be immediately after a Deconsolidation Event, the common parent corporation and including any corporation or other
entity which may become a member of such group from time to time. 
 “[SUBSIDIARY] Separate Federal Tax Liability” means an amount equal to
the Tax liability that [SUBSIDIARY] and each [SUBSIDIARY] Affiliate would have incurred if they had filed a Tax Return with respect to U.S. federal Income Taxes filed on a consolidated basis separate from the members of the BridgeBio Group, for the
relevant Tax period, and such amount shall be computed by BridgeBio (i) in a manner consistent with (a) general Tax accounting principles, (b) the Code and the Treasury regulations promulgated thereunder, and (c) to the extent
allowed by applicable law, past practice, if any, and (ii) taking into account any Tax Asset attributable to [SUBSIDIARY] or any [SUBSIDIARY] Affiliate pursuant to Section 4.3. 

  
 3 

 “[SUBSIDIARY] Separate Other Tax Liability” means an amount equal to any and all Income
Taxes (other than any U.S. federal Income Taxes) for a relevant Tax period with respect to or as a result of, assets, or activities of [SUBSIDIARY] and the [SUBSIDIARY] Affiliates, determined on a “with and without” basis, by calculating
the amount of the excess (if any) of (i) the net amount of Taxes shown as due and payable on a Combined Return with respect to such relevant Tax period, as filed, over (ii) the net amount of Taxes that would be shown as due and payable on
such Combined Return if such Combined Return were recalculated excluding [SUBSIDIARY] and the [SUBSIDIARY] Affiliates. 
 “[SUBSIDIARY] Transfer
Agent” means the financial institution selected by [SUBSIDIARY] to track the individuals and entities that own [SUBSIDIARY] stock. 

“Estimated Tax Installment Date” means, with respect to U.S. federal Income Taxes, the estimated Tax installment due dates prescribed in
Section 6655(c) of the Code and, in the case of any other Tax, means any other date on which an installment payment of any estimated amount of such Tax is required to be made. 

“Final Determination” shall mean the final resolution of liability for any Tax for any Taxable Period, by or as a result of: (i) a final
and unappealable decision, judgment, decree or other order by any court of competent jurisdiction; (ii) a final settlement with the IRS, a closing agreement or accepted offer in compromise under Sections 7121 or 7122 of the Code, or a
comparable agreement under the laws of other jurisdictions, which resolves the entire Tax liability for any Taxable Period; (iii) any allowance of a refund or credit in respect to an overpayment of Tax, but only after the expiration of all
periods during which such refund may be recovered by the jurisdiction imposing the Tax; or (iv) any other final disposition, including by any reason of the expiration of the statute of limitations. 

“Income Tax” means any U.S. federal, state, local or other Tax determined (in whole or in part) by reference to net income, worth, gross
receipts or capital, or any Taxes imposed in lieu of such a tax. For the avoidance of doubt, the term “Income Tax” includes any franchise tax or any Taxes imposed in lieu of such a tax. 

“Income Tax Return” means any Tax Return relating to any Income Tax. 

“Independent Accountant” has the meaning set forth in Section 3.1. 

“Initial Public Offering” or “IPO” has the meaning set forth in the Preamble. 

“Initial Public Offering Date” or “IPO Date” means the close of business on the date which the BridgeBio Registration
Statement is declared effective by the U.S. Securities and Exchange Commission. 
 “IRS” means the United States Internal Revenue Service
or any successor thereto, including its agents, representatives, and attorneys. 
 “Non-Income Tax
Return” means any Tax Return relating to any Tax other than an Income Tax. 
 “Officer’s Certificate” means a
letter executed by an officer of BridgeBio or [SUBSIDIARY] and provided to Tax Counsel as a condition to the completion of a Tax Opinion or Supplemental Tax Opinion. 

“Owed Party” has the meaning set forth in Section 5.5. 

  
 4 

 “Owing Party” has the meaning set forth in Section 5.5. 

“Party” and “Parties” has the meaning set forth in the Preamble. 

“Payment Period” has the meaning set forth in Section 5.5(e). 

“Post-Deconsolidation Period” means any Taxable Period beginning after the date of a Deconsolidation Event. 

“Post-IPO Period” means any Taxable Period beginning after the IPO Date. 

“Pre-Deconsolidation Period” means any Taxable Period beginning on or before the date of a
Deconsolidation Event. 
 “Pre-Distribution Period” has the meaning set forth in
Section 8.4(b). 
 “Ruling” means (i) any private letter ruling issued by the IRS in connection with a Distribution in response
to a request for such a private letter ruling filed by BridgeBio (or any BridgeBio Affiliate) prior to the date of a Distribution, and (ii) any similar ruling issued by any other Taxing Authority addressing the application of a provision of the
laws of another jurisdiction to a Distribution. 
 “Ruling Document” means (i) the request for a Ruling filed with the IRS, together
with any supplemental filings or other materials subsequently submitted on behalf of BridgeBio, its subsidiaries and shareholders to the IRS, the appendices and exhibits thereto, and any Ruling issued by the IRS to BridgeBio (or any BridgeBio
Affiliate) in connection with a Distribution and (ii) any similar filings submitted to, or Rulings issued by, any other Taxing Authority in connection with a Distribution. 

“Sole Responsibility Item” means any Tax Item for which the non-Controlling Party has the entire
economic liability under this Agreement. 
 “Straddle IPO Period” means any Taxable Period beginning on or before the IPO Date and ending
after the IPO Date. 
 “Supplemental Ruling” means (i) any ruling (other than a Ruling) issued by the IRS in connection with a
Distribution, and (ii) any similar ruling issued by any other Taxing Authority addressing the application of a provision of the laws of another jurisdiction to a Distribution. 

“Supplemental Ruling Documents” means (i) the request for a Supplemental Ruling, together with any supplemental filings or other
materials subsequently submitted, the appendices and exhibits thereto, and any Supplemental Rulings issued by the IRS in connection with a Distribution and (ii) any similar filings submitted to, or rulings issued by, any other Taxing Authority
in connection with a Distribution. 
 “Supplemental Tax Opinion” has the meaning set forth in Section 8.6. 

“Tax Asset” means any Tax Item that has accrued for Tax purposes, but has not been realized during the Taxable Period in which it has accrued
and that could reduce a Tax in another Taxable Period, including, but not limited to, a net operating loss, net capital loss, investment tax credit, foreign tax credit, charitable deduction or credit related to alternative minimum tax or any other
Tax credit. 

  
 5 

 “Tax Benefit” means a reduction in the Tax liability of a Party for any Taxable Period.
Except as otherwise provided in this Agreement, a Tax Benefit shall be deemed to have been realized or received from a Tax Item in a Taxable Period only if and to the extent that the cash Tax liability of the Taxpayer, after taking into account the
effect of the Tax Item on the Tax liability of the Taxpayer in the current Taxable Period and all prior Taxable Periods, is less than it would have been had such Tax liability determined without regard to such Tax Item. 

“Tax Control” means ownership of an amount of equity of a corporation that represents both (i) control of that corporation within
the meaning of Section 368(c) of the Code and (ii) the 80 percent voting and value test set forth in Section 1504(a)(2) of the Code. 

“Tax Counsel” means a nationally recognized law or accounting firm selected by BridgeBio to provide a Tax Opinion. 

“Tax Detriment” means an increase in the Tax liability of a Taxpayer for any Taxable Period. Except as otherwise provided in this Agreement,
a Tax Detriment shall be deemed to have been realized or incurred from a Tax Item in a Taxable Period only if and to the extent that the Tax liability of the Taxpayer for such period, after taking into account the effect of the Tax Item on the Tax
liability of such Taxpayer in the current period and all prior periods, is more than it would have been had such Tax liability been determined without regard to such Tax Item. 

“Tax Free Status of the Distribution” means the nonrecognition of taxable gain or loss for U.S. federal Income Tax purposes to the BridgeBio
Group and BridgeBio’s stockholders in connection with a Distribution. 
 “Tax Item” means any item of income, gain , loss, deduction,
expense or credit, or other attribute that may have the effect of increasing or decreasing any Tax. 
 “Tax Opinion” means an opinion
issued by Tax Counsel as one of the conditions to completing a Distribution addressing certain U.S. federal Income Tax consequences of a Distribution under Section 355 of the Code. 

“Tax Return” means any return, report, certificate, form or similar statement or document (including all information attached thereto and any
information return, amended tax return, claim for refund or declaration of estimated Tax) required to, or filed with, a Taxing Authority in connection with the determination, assessment, or collection of any Tax or the administration of any laws,
regulations or administrative requirements relating to any Tax. 
 “Taxable Period” means any taxable year or portion thereof beginning on
or after the date first written above with respect to which a Consolidated Return is properly filed on behalf of the BridgeBio which includes [SUBSIDIARY] or, in the case of any Combined Return, any such taxable year or portion thereof with respect
to which a Combined Return is filed by BridgeBio or any BridgeBio Affiliate which includes [SUBSIDIARY] or any [SUBSIDIARY] Affiliate. 

“Taxes” mean all federal, state, local or other taxes, charges, fees, duties, levies, imposts, rates or other assessments, including income,
gross receipts, net worth, excise, margin, property, sales, use, license, capital stock, transfer, franchise, payroll, withholding, social security, value added or other taxes, (including any interest, penalties or additions attributable thereto)
and a “Tax” shall mean any one of such Taxes. 
 “Taxing Authority” means any governmental authority or any subdivision,
agency, commission or authority thereof, or any quasi-governmental or private body having jurisdiction over the assessment, determination, collection or imposition of any Tax (including the IRS). 

  
 6 

 “Taxpayer” means any taxpayer and its Affiliated Group or similar group of entities as
defined under corresponding provisions of the laws of any other jurisdiction of which such taxpayer is a member. 
 Section 2.
Agreement to Join in Tax Returns 
 2.1 Joining in Consolidated Returns and Combined Returns. BridgeBio, each BridgeBio Affiliate,
[SUBSIDIARY] and each [SUBSIDIARY] Affiliate intend that the provisions of this Agreement shall apply to any and all situations in which any Taxes are imposed by any Taxing Authority and any Tax Return is required to be filed, or BridgeBio
determines that it is advisable to file, on behalf of more than one Party to this Agreement on a Consolidated Return or Combined Return basis for any Taxable Period so long as this Agreement may remain in effect. Confirming this intent: 

(a) Each BridgeBio Affiliate, [SUBSIDIARY], and [SUBSIDIARY] Affiliate agrees to join with BridgeBio in any (i) Consolidated Return for
any Taxable Period for which BridgeBio files a Consolidated Return that includes such BridgeBio Affiliate, [SUBSIDIARY], and [SUBSIDIARY] Affiliate, and (ii) any Combined Return for any Taxable Period for which BridgeBio files a Combined Return
that includes such BridgeBio Affiliate, [SUBSIDIARY] and [SUBSIDIARY] Affiliate. 
 (b) The Parties agree that BridgeBio is hereby authorized
to determine, in its sole discretion, whether any and each of the BridgeBio Affiliates, [SUBSIDIARY] or any and each of the [SUBSIDIARY] Affiliates will be included in the filing of a Consolidated Return or a Combined Return, or whether any
BridgeBio Affiliate, [SUBSIDIARY] or any [SUBSIDIARY] Affiliate will file a separate stand-alone Income Tax Return where the choice is available. 
 2.2
Continuing Tax Covenants. Each of BridgeBio (for itself and each BridgeBio Affiliate) and [SUBSIDIARY] (for itself and each [SUBSIDIARY] Affiliate) agrees: (a) not to take any action reasonably expected to result in an increased Tax
Detriment to the other Party, a reduction in a Tax Asset of the other or an increased liability to the other Party under this Agreement; (b) to take any action reasonably requested by the other Party that would reasonably be expected to result
in a Tax Benefit or to avoid a Tax Detriment to the other Party, provided, in either such case, that the taking or refraining to take such action does not result in any additional cost not fully compensated for by the other Party or any other
adverse effect to such Party; and (c) to use their reasonable best efforts to conclude any other agreements necessary to carry out the intent of this Section 2. The Parties hereby acknowledge that the preceding sentence is not intended to
limit, and therefore shall not apply to, the rights of the Parties with respect to matters otherwise covered by this Agreement. 

Section 3. Preparation and Filing of Tax Returns 

3.1 Tax Return Preparation. The Parties hereby agree that BridgeBio shall have the exclusive right, in its sole discretion, with respect to any Tax
Return described in Section 3.2, to determine: 
 (a) the manner in which such Tax Return shall be prepared and filed, including, but
not limited to, the elections, method of accounting, positions, conventions, and principles of taxation to be used and the manner in which any Tax Item shall be reported; 

(b) whether any extensions shall be requested; 

(c) whether any amended Tax Return shall be filed; 

(d) whether any claims for refund shall be made; 

  
 7 

 (e) whether any refunds shall be paid by way of a refund or credited against any liability
for the related Tax; and 
 (f) whether to retain outside Parties to prepare and or review any such Tax Return; 

provided, however, that BridgeBio shall consult with [SUBSIDIARY] prior to changing any method of accounting if such action would solely impact
[SUBSIDIARY] or [SUBSIDIARY] Affiliates. In the case of any Consolidated Return or Combined Return with respect to a Straddle IPO Period or a Post-IPO Period that results in a [SUBSIDIARY] Separate Federal Tax Liability or a [SUBSIDIARY] Separate
Other Tax Liability in excess of one hundred thousand dollars ($100,000), BridgeBio shall provide to [SUBSIDIARY] a pro forma draft of the portion of such Tax Return that relates to the [SUBSIDIARY] Separate Federal Tax Liability or [SUBSIDIARY]
Separate Other Tax Liability, as the case may be, and a statement showing in reasonable detail BridgeBio’s calculation of the [SUBSIDIARY] Separate Federal Tax Liability or [SUBSIDIARY] Separate Other Tax Liability (including copies of all
worksheets and other materials used in preparation thereof), as applicable, at least twenty-one (21) days prior to the due date (taking into account any applicable extensions) for the filing of such Tax Return for [SUBSIDIARY]’s review and
comment. [SUBSIDIARY] shall provide its comments to BridgeBio at least ten (10) days prior to the due date (taking into account any applicable extensions) for the filing of such Tax Return. In the case of a dispute regarding the reporting of
any Tax Item on such Tax Return or the requesting of a change of method of accounting which would solely impact [SUBSIDIARY] or [SUBSIDIARY] Affiliates, which the Parties cannot resolve, BridgeBio and [SUBSIDIARY] shall jointly retain a nationally
recognized accounting firm that is mutually agreed upon by BridgeBio and [SUBSIDIARY] (the “Independent Accountant”) to determine whether the proposed reporting of BridgeBio or [SUBSIDIARY] is more appropriate. If BridgeBio and
[SUBSIDIARY] are unable to agree, the Independent Accountant shall be BDO USA, LLP. The relevant Tax Item shall be reported in the manner that the Independent Accountant determines is more appropriate, and such determination shall be final and
binding on BridgeBio and [SUBSIDIARY]. If [SUBSIDIARY] has not provided its comments on the pro forma draft of the portion of the Tax Return, or in the case of a dispute regarding the reporting of any Tax Item, such dispute has not been resolved by
the due date (taking into account any applicable extensions) for the filing of any Tax Return, BridgeBio shall file such Tax Return reporting all Tax Items in the manner as originally set forth on the pro forma draft of the portion of the Tax Return
provided to [SUBSIDIARY]; provided, however, that BridgeBio agrees that it will thereafter file an amended Tax Return, if necessary, reporting any disputed Tax Item in the manner determined by the Independent Accountant, and any other
Tax Item as agreed upon by BridgeBio and [SUBSIDIARY]. The fees and expenses incurred in retaining the Independent Accountant shall be borne equally by BridgeBio and [SUBSIDIARY], except that if the Independent Accountant determines that the
proposed reporting of the disputed Tax Item(s) submitted to the Independent Accountant for its determination by a Party is frivolous, has not been asserted in good faith or for which there is not “substantial authority”, one hundred
percent (100%) of the fees and expenses of the Independent Accountant shall be borne by such Party. 
 3.2 BridgeBio Tax Returns. Subject to the
other applicable provisions of this Agreement, BridgeBio shall have sole and exclusive responsibility for the preparation and filing of: 

(a) All Consolidated Returns and all Combined Returns with respect to BridgeBio, any BridgeBio Affiliates, [SUBSIDIARY], and any [SUBSIDIARY]
Affiliates for any Taxable Period; 
 (b) All Income Tax Returns (other than Consolidated Returns and Combined Returns) with respect to
BridgeBio and/or any BridgeBio Affiliates for any Taxable Period; and 
 (c) All Non-Income Tax Returns with respect to BridgeBio, any
BridgeBio Affiliate or the BridgeBio Business or any part thereof for any Taxable Period. 

  
 8 

 3.3 [SUBSIDIARY] Tax Returns. Subject to the other applicable provisions of this Agreement,
[SUBSIDIARY] shall have sole and exclusive responsibility for the preparation and filing of: 
 (a) All Tax Returns for any Taxable Period
with respect to [SUBSIDIARY] and any [SUBSIDIARY] Affiliates ending prior to the Straddle IPO Period or the Post-IPO Period; 
 (b) All
Income Tax Returns (other than Consolidated Returns and Combined Returns and those Tax Returns set forth in Section 3.3(a)) with respect to [SUBSIDIARY] and or any [SUBSIDIARY] Affiliate for any Taxable Period; and 

(c) All Non-Income Tax Returns (other than those Tax Returns set forth in Section 3.3(a)) with respect to [SUBSIDIARY] and any
[SUBSIDIARY] Affiliate for any Taxable Period. 
 [SUBSIDIARY] agrees that all Tax Returns prepared by [SUBSIDIARY] pursuant to this Section 3.3
involving a position, election or other matter that may also be reported on any Tax Return prepared by BridgeBio pursuant to Section 3.2 shall be prepared consistently with such Tax Return prepared by BridgeBio. [SUBSIDIARY] and BridgeBio
shall cooperate in order to ensure that any Tax Returns prepared by [SUBSIDIARY] covered by the preceding sentence are consistent with such Tax Returns prepared by BridgeBio. 

3.4 Manner of Tax Return Preparation. Unless otherwise required by a Taxing Authority, the Parties hereby agree to prepare and to file all Tax Returns,
and to take all other actions, in a manner consistent with: 
 (a) this Agreement; 

(b) any Tax Opinion; 
 (c) any
Supplemental Tax Opinion; 
 (d) any Ruling; and 

(e) any Supplemental Ruling. 
 3.5 Designation
of BridgeBio. Each BridgeBio Affiliate, [SUBSIDIARY], and each [SUBSIDIARY] Affiliate hereby irrevocably designates BridgeBio as its agent for the purpose of taking any and all actions necessary or incidental to the filing of Consolidated
Returns and Combined Returns. Each BridgeBio Affiliate, [SUBSIDIARY] and each [SUBSIDIARY] Affiliate agrees to furnish BridgeBio with any and all information requested by BridgeBio in order to carry out the provisions of this Agreement; to cooperate
with BridgeBio in filing any Tax Return contemplated by this Agreement; to take such actions as BridgeBio may request, including but not limited to the filing of all elections and the filing of requests for the extension of time within which to file
Tax Returns; and to cooperate in connection with any Audit or Tax Item. 
 3.6 Timely Filing. The Parties agree that all Tax Returns shall be filed on
a timely basis (taking into account applicable extensions) by the Party responsible for filing such returns under this Agreement. 

  
 9 

 Section 4. Liability for Taxes; Computation of Tax Liability 

4.1 Taxes of [SUBSIDIARY]. [SUBSIDIARY] and each [SUBSIDIARY] Affiliate shall be jointly and severally liable for the following Taxes and shall be
entitled to receive and retain all refunds of Taxes previously incurred by [SUBSIDIARY], any [SUBSIDIARY] Affiliate, or [SUBSIDIARY] Business with respect to such Taxes: 

(a) All Taxes with respect to Tax Returns described in Section 3.2(a) of this Agreement to the extent that such Taxes are related to
(i) the [SUBSIDIARY] Separate Federal Tax Liability, (ii) the [SUBSIDIARY] Separate Other Tax Liability or (iii) the [SUBSIDIARY] Business, for any Taxable Period; 

(b) All Taxes with respect to Tax Returns described in Section 3.3 of this Agreement; 

(c) All Taxes imposed by any Taxing Authority with respect to [SUBSIDIARY], any [SUBSIDIARY] Affiliate or the [SUBSIDIARY] Business (other than
in connection with the required filing of a Tax Return described in Sections 3.2(a) or 3.3 of this Agreement) for any Taxable Period. 
 4.2 Taxes of
BridgeBio. BridgeBio shall be liable for the following Taxes, and shall be entitled to receive and retain all refunds of Taxes previously incurred by BridgeBio, any BridgeBio Affiliate, or the BridgeBio Business with respect to such Taxes: 

(a) Except as provided in Section 4.1 of this Agreement, all Taxes with respect to Section 3.2(a) of this Agreement; 

(b) All Taxes with respect to Tax Returns described in Sections 3.2(b) and 3.2(c) of this Agreement; and 

(c) All Taxes imposed by any Taxing Authority with respect to BridgeBio, any BridgeBio Affiliate, or the BridgeBio Business (other than in
connection with the required filing a Tax Return described in Section 3.2(a), 3.2(b) or 3.2(c) of this Agreement) for any Taxable Period. 
 4.3 Tax
Liability, Refunds and Credits; Tax Benefits. Notwithstanding Sections 4.1 and 4.2 of this Agreement, (i) BridgeBio shall be liable for all Taxes incurred by any person with respect to the BridgeBio Business for all Taxable Periods and
shall be entitled to all refunds and credits of Taxes previously incurred by any person with respect to such Taxes, and (ii) [SUBSIDIARY] and each [SUBSIDIARY] Affiliate shall be jointly and severally liable for all Taxes incurred by any person
with respect to the [SUBSIDIARY] Business for all Taxable Periods and shall be entitled to all refunds and credits of Taxes previously incurred by any person with respect to such Taxes. If for any Taxable Period for which a Consolidated Return or
Combined Return is filed, any BridgeBio Affiliate, [SUBSIDIARY] or any [SUBSIDIARY] Affiliate has a Tax Asset that reduces the liability of the Affiliated Group on such Consolidated Return or Combined Return, BridgeBio agrees to pay the BridgeBio
Affiliate, [SUBSIDIARY] or the [SUBSIDIARY] Affiliate, as applicable, an amount equal to the Tax Benefit, determined on a “with and without” basis. For the avoidance of doubt, such payment from BridgeBio only will be required in the event
that the use of such Tax Asset causes the applicable BridgeBio Affiliate, [SUBSIDIARY] or [SUBSIDIARY] Affiliate to incur a cash Tax liability, or be treated as incurring a cash Tax liability on a Consolidated Return or Combined Return pursuant to
this Section 4.3, that could have been reduced or avoided through the use of such Tax Asset had such Tax Asset not been used by BridgeBio under this Section 4.3. 

4.4 Computation of Amounts. With respect to Tax Returns for Taxable Periods in the Straddle IPO Period and the Post-IPO Period, BridgeBio shall provide
[SUBSIDIARY] with a written calculation in reasonable detail (including upon reasonable request, copies of all work sheets and other materials used in preparation thereof) setting forth the amount of any [SUBSIDIARY] Separate Federal Tax Liability
or [SUBSIDIARY] Other Tax Liability, or estimated [SUBSIDIARY] Separate Federal Tax Liability or 

  
 10 

 
[SUBSIDIARY] Separate Other Tax Liability, any other Taxes related to the [SUBSIDIARY] Business and any payments owed for a Tax Benefit pursuant to Section 4.3. Such written calculation
shall also include the portion of the expenses incurred by BridgeBio in the preparation and filing of such Tax Returns attributable to [SUBSIDIARY] and each [SUBSIDIARY] Affiliate, as determined in BridgeBio’s reasonable discretion.
[SUBSIDIARY] shall have the right to review and comment on such calculation. Any dispute with respect to such calculation shall be resolved pursuant to Section 10.3 of this Agreement; provided, however, that, notwithstanding any
dispute with respect to any such calculation, in no event shall any payment attributable to the amount of any [SUBSIDIARY] Separate Federal Tax Liability, [SUBSIDIARY] Separate Other Tax Liability, estimated [SUBSIDIARY] Separate Federal Tax
Liability or estimated [SUBSIDIARY] Separate Other Tax Liability be paid later than the date provided in Section 5 of this Agreement. 

Section 5. Payments of Taxes 

5.1 Estimated Tax Payments. Not later than twenty-five (25) business days after each Estimated Tax Installment Date with respect to a Taxable
Period for which a Consolidated Return or a Combined Return will be filed, BridgeBio shall provide [SUBSIDIARY] with (i) a written notice setting forth the amount payable by [SUBSIDIARY] in respect of any estimated [SUBSIDIARY] Separate Federal
Tax Liability or estimated [SUBSIDIARY] Separate Other Tax Liability, as applicable, that [SUBSIDIARY] otherwise would have been required to pay to a Taxing Authority on such Estimated Tax Installment Date and (ii) a computation of such amount
(pursuant to Section 4.4 of this Agreement). [SUBSIDIARY] shall pay to BridgeBio on behalf of the [SUBSIDIARY] Group an amount equal to the amount of any such estimated [SUBSIDIARY] Separate Federal Tax Liability or estimated [SUBSIDIARY]
Separate Other Tax Liability, as applicable, in accordance with Section 5.5 of this Agreement. 
 5.2 True-Up Payments. No later than twenty
(20) business days after receipt of the computation of any [SUBSIDIARY] Separate Federal Tax Liability, any [SUBSIDIARY] Separate Other Tax Liability, any other Taxes related to the [SUBSIDIARY] Business and any payments owed for a Tax Benefit
pursuant to Section 4.3 under Section 4.4 of this Agreement, [SUBSIDIARY] shall pay to BridgeBio, or BridgeBio shall pay to [SUBSIDIARY], as appropriate, an amount equal to the difference, if any, between the [SUBSIDIARY] Separate Federal
Tax Liability, the [SUBSIDIARY] Separate Other Tax Liability, any other Taxes related to the [SUBSIDIARY] Business and any payments owed for a Tax Benefit pursuant to Section 4.3, as applicable, and the aggregate amount paid by [SUBSIDIARY]
with respect to such period under Section 5.1 of this Agreement. 
 5.3 Indemnity for Amounts Required to be Paid. BridgeBio and each member of
the BridgeBio Group shall jointly and severally indemnify [SUBSIDIARY], each [SUBSIDIARY] Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any and all Taxes for which BridgeBio or any
BridgeBio Affiliate is liable under this Agreement and any losses, costs, damages or expenses, including reasonable attorneys’ fees and out-of-pocket costs, that are attributable to, or result from, the failure of BridgeBio, any BridgeBio
Affiliate or any director, officer or employee to make any payment required to be made under this Agreement. [SUBSIDIARY] and each member of the [SUBSIDIARY] Group shall jointly and severally indemnify BridgeBio, each BridgeBio Affiliate, and their
respective directors, officers and employees, and hold them harmless from and against any and all Taxes for which [SUBSIDIARY] or any [SUBSIDIARY] Affiliate is liable under this Agreement and any losses, costs, damages or expenses, including
reasonable attorneys’ fees and out-of-pocket costs, that are attributable to, or result from, the failure of [SUBSIDIARY], any [SUBSIDIARY] Affiliate or any director, officer or employee to make any payment required to be made under this
Agreement. Nothing in this Agreement shall be construed as a guarantee of the existence or amount of any loss, credit, carryforward, basis or other Tax Item, whether past, present or future, of BridgeBio, any BridgeBio Affiliate, [SUBSIDIARY] or any
[SUBSIDIARY] Affiliate. In addition, for the avoidance of doubt, for purposes of determining any amount owed between the Parties hereto, all such determinations shall be made without regard to any financial accounting tax asset or liability or other
financial accounting items. 

  
 11 

 5.4 Payments of Refunds, Credits and Reimbursements. If one Party receives a refund or credit of any
Tax to which the other Party is entitled pursuant to Section 4.3 of this Agreement, the Party receiving such refund or credit shall pay to the other Party the amount of such refund or credit pursuant to Section 5.5 of this Agreement. If
one Party pays a Tax with respect to which the other Party is liable or responsible for pursuant to Sections 4.1 through 4.3 of this Agreement, then the liable or responsible Party shall pay to the other Party the amount of such Tax pursuant to
Section 5.5 of this Agreement. 
 5.5 Payments Under This Agreement. In the event that one Party (the “Owing Party”) is required
to make a payment to another Party (the “Owed Party”) pursuant to this Agreement, then such payments shall be made according to this Section 5.5. 

(a) In General. All payments shall be made to the Owed Party or to the appropriate Taxing Authority as specified by the Owed Party
within the time prescribed for payment in this Agreement, or if no period is prescribed, within thirty (30) days after delivery of written notice of payment owing together with a computation of the amounts due. 

(b) Treatment of Payments. Unless otherwise required by any Final Determination, the Parties agree that any payments made by one Party
to another Party pursuant to this Agreement (other than (i) payments for the [SUBSIDIARY] Separate Federal Tax Liability or [SUBSIDIARY] Separate Other Tax Liability for any Post-Deconsolidation Period, (ii) payments of interest pursuant
to Section 5.5(e) of this Agreement and (iii) payments of After Tax Amounts pursuant to Section 5.5(d) of this Agreement) shall be treated for all Tax and financial accounting purposes as nontaxable payments (dividend distributions or
capital contributions, as the case may be) made prior to the Deconsolidation Event and, accordingly, as not includible in the taxable income of the recipient or as deductible by the payor. 

(c) Prompt Performance. All actions required to be taken (including payments) by any Party under this Agreement shall be performed
within the time prescribed for performance in this Agreement, or if no period is prescribed, such actions shall be performed promptly. 
 (d)
After Tax Amounts. If pursuant to a Final Determination it is determined that the receipt or accrual of any payment made under this Agreement (other than payments of interest pursuant to Section 5.5(e) of this Agreement) is subject to
any Tax, the Party making such payment shall be liable for (a) the After Tax Amount with respect to such payment and (b) interest at the rate described in Section 5.5(e) of this Agreement on the amount of such Tax from the date such
Tax accrues through the date of payment of such After Tax Amount. A Party making a demand for a payment pursuant to this Agreement and for a payment of an After Tax Amount with respect to such payment shall separately specify and compute such After
Tax Amount. However, a Party may choose not to specify an After Tax Amount in a demand for payment pursuant to this Agreement without thereby being deemed to have waived its right subsequently to demand an After Tax Amount with respect to such
payment. [SUBSIDIARY]’s liability for any and all payments of the [SUBSIDIARY] Separate Federal Tax Liability or [SUBSIDIARY] Separate Other Tax Liability for any Post-Deconsolidation Period shall be increased by the After Tax Amount with
respect to such payment and decreased by the corresponding Tax Benefit, if any, attributable to such [SUBSIDIARY] Separate Federal Tax Liability or [SUBSIDIARY] Separate Other Tax Liability. 

  
 12 

 (e) Interest. Payments pursuant to this Agreement that are not made within the period
prescribed in this Agreement (the “Payment Period”) shall bear interest for the period from and including the date immediately following the last date of the Payment Period through and including the date of payment at a per annum
rate equal to the prime rate as published in The Wall Street Journal on the last day of such Payment Period. Such interest will be payable at the same time as the payment to which it relates and shall be calculated on the basis of a year of three
hundred sixty-five (365) days and the actual number of days for which due. 
 Section 6. Tax Adjustments 

6.1 Redetermination of Taxes. In the event of any adjustment to the Consolidated Returns or Combined Returns as filed (whether by reason of an amended
return, claim for refund, any Audit or adjustment by any Taxing Authority, or by proper judicial action), the liability of BridgeBio, the BridgeBio Affiliates, [SUBSIDIARY] and the [SUBSIDIARY] Affiliates under Sections 4.1 through 4.3 shall be
redetermined to give effect to any such adjustment as if it had been made as part of the original computation of Tax liability. Any payment thereby required by Sections 4.1 through 4.3 shall be made within a reasonable time after assessment or
agreement for payments of additional Tax liability is made or refunds of Taxes paid are received. Such reasonable time shall generally be five (5) days before the payment due date or expected payment due date, or five (5) days after
refunds are received and the share of each of BridgeBio, the BridgeBio Affiliates, [SUBSIDIARY] and the [SUBSIDIARY] Affiliates has been determined. 
 6.2
Interest and Penalties. If any interest or penalties are to be paid or received as a result of an adjustment to an applicable Consolidated Return or Combined Return for a Taxable Period, such interest and penalties shall be allocated to the
Parties to this Agreement in the ratio of each Party’s change in Tax liability bears to the total change in Tax liability. 

Section 7. Deconsolidation Events 

7.1 Allocations Applicable to a Deconsolidation Event. In the case of a Deconsolidation Event, all Tax computations for (a) any Pre-Deconsolidation
Periods ending on the date of the Deconsolidation Event and (b) the immediately following Taxable Period of [SUBSIDIARY] or any [SUBSIDIARY] Affiliate, shall be made pursuant to the principles of Treasury Regulation Section 1.1502-76(b)
(or of a corresponding provision under the laws of other jurisdictions), as reasonably determined by BridgeBio, taking into account all reasonable suggestions made by [SUBSIDIARY] with respect thereto. Notwithstanding anything else in this
Agreement, [SUBSIDIARY] and any [SUBSIDIARY] Affiliate shall continue to be liable pursuant to the terms of this Agreement for any Pre-Deconsolidation Periods. 

7.2 Tax Assets. In the case of a Deconsolidation Event, BridgeBio and [SUBSIDIARY] shall cooperate in determining the allocation of any Tax Assets to be
allocated to BridgeBio, each BridgeBio Affiliate, [SUBSIDIARY], and each [SUBSIDIARY] Affiliate. The Parties hereby agree that in the absence of controlling legal authority or unless otherwise provided under this Agreement, Tax Assets shall be
allocated to the legal entity that is required under Section 4 of this Agreement to bear the liability for the Tax associated with such Tax Asset, or in the case where no Party is required hereunder to bear such liability, the Party that
incurred the cost or burden associated with the creation of such Tax Asset. 
 Section 8. Distribution
Taxes 
 8.1 Liability of BridgeBio for Distribution Taxes. Although no Party has any plan or intent to effectuate a Distribution, the Parties
have set forth how certain Tax matters with respect to a Distribution would be handled in the event that, as a result of changed circumstances, a Distribution occurs. In the event of a Distribution, notwithstanding Sections 4.1 through 4.3 of this
Agreement, BridgeBio and each BridgeBio Affiliate shall be jointly and severally liable for any Distribution Taxes, to the extent that such Distribution Taxes are attributable to, caused by, or result from, one or more of the following: 

  
 13 

 (a) any action or omission by BridgeBio (or any BridgeBio Affiliate) inconsistent with any
information, covenant, representation, or material related to BridgeBio, any BridgeBio Affiliate, or the BridgeBio Business in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents, Supplemental Ruling Documents,
Ruling, or Supplemental Ruling (for the avoidance of doubt, disclosure by BridgeBio (or any BridgeBio Affiliate) to [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) of any action or fact that is inconsistent with any information, covenant,
representation, or material submitted to Tax Counsel, the IRS, or other Taxing Authority, as applicable, in connection with an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents, Supplemental Ruling Documents,
Ruling, or Supplemental Ruling shall not relieve BridgeBio (or any BridgeBio Affiliate) of liability under this Agreement); 
 (b) any action
or omission by BridgeBio (or any BridgeBio Affiliate) after the date of a Distribution (including any act or omission that is in furtherance of, connected to, or part of a plan or series of related transactions (within the meaning of
Section 355(e) of the Code) occurring on or prior to the date of a Distribution) including a cessation, transfer to affiliates or disposition of the active trades or businesses of BridgeBio (or any BridgeBio Affiliate), stock buyback or payment
of an extraordinary dividend; 
 (c) any acquisition of any stock or assets of BridgeBio (or any BridgeBio Affiliate) by one or more other
persons (other than [SUBSIDIARY] or a [SUBSIDIARY] Affiliate) prior to or following a Distribution; or 
 (d) any issuance of stock by
BridgeBio (or any BridgeBio Affiliate), or change in ownership of stock in BridgeBio (or any BridgeBio Affiliate). 
 8.2 Liability of [SUBSIDIARY] for
Distribution Taxes. In the event of a Distribution, notwithstanding Sections 4.1 through 4.3 of this Agreement, [SUBSIDIARY] and each [SUBSIDIARY] Affiliate shall be jointly and severally liable for any Distribution Taxes, to the extent that
such Distribution Taxes are attributable to, caused by, or result from, one or more of the following: 
 (a) any action or omission by
[SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) inconsistent with any information, covenant, representation, or material related to [SUBSIDIARY], any [SUBSIDIARY] Affiliate, or the [SUBSIDIARY] Business in an Officer’s Certificate, Tax Opinion,
Supplemental Tax Opinion, Ruling Documents, Supplemental Ruling Documents, Ruling, or Supplemental Ruling (for the avoidance of doubt, disclosure by [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) to BridgeBio (or any BridgeBio Affiliate) of any action
or fact that is inconsistent with any information, covenant, representation, or material submitted to Tax Counsel, the IRS, or other Taxing Authority, as applicable, in connection with an Officer’s Certificate, Tax Opinion, Supplemental Tax
Opinion, Ruling Documents, Supplemental Ruling Documents, Ruling, or Supplemental Ruling shall not relieve [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) of liability under this Agreement); 

(b) any action or omission by [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) after the date of a Distribution (including any act or omission that
is in furtherance of, connected to, or part of a plan or series of related transactions (within the meaning of Section 355(e) of the Code) occurring on or prior to the date of a Distribution) including a cessation, transfer to affiliates or
disposition of the active trades or businesses of [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate), stock buyback or payment of an extraordinary dividend; 

  
 14 

 (c) any acquisition of any stock or assets of [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate)
by one or more other persons (other than BridgeBio or any BridgeBio Affiliate) prior to or following a Distribution; or 
 (d) any issuance
of stock by [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) after a Distribution, including any issuance pursuant to the exercise of employee stock options or other employment related arrangements or the exercise of warrants, or change in ownership of
stock in [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) after a Distribution. 
 8.3 Other Distribution Taxes. BridgeBio and each BridgeBio Affiliate
shall be jointly and severally liable for fifty percent (50%) and [SUBSIDIARY] and each [SUBSIDIARY] Affiliate shall be jointly and severally liable for fifty percent (50%) of any Distribution Taxes not otherwise allocated by Sections 8.1
and 8.2 of this Agreement. 
 8.4 [SUBSIDIARY] Distribution Restrictions. 

(a) [SUBSIDIARY] agrees that, so long as a Distribution could, in the reasonable discretion of BridgeBio, be effectuated, [SUBSIDIARY] will not
knowingly take or fail to take, or permit any [SUBSIDIARY] Affiliate to knowingly take or fail to take, any action that could reasonably be expected to preclude BridgeBio’s ability to effectuate a Distribution. In the event of a Distribution,
[SUBSIDIARY] agrees that (i) it will take, or cause any [SUBSIDIARY] Affiliate to take, any action reasonably requested by BridgeBio in order to enable BridgeBio to effectuate a Distribution and (ii) it will not take or fail to take, or
permit any [SUBSIDIARY] Affiliate to take or fail to take, any action where such action or failure to act would be inconsistent with any information, covenant, representation, or material that relates to facts or matters related to [SUBSIDIARY] (or
any [SUBSIDIARY] Affiliate) or within the control of [SUBSIDIARY] and is contained in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents, Supplemental Ruling Documents, Ruling, or Supplemental Ruling (except where
such information, covenant, representation, or material was not previously disclosed to [SUBSIDIARY]) other than as permitted by Section 8.6 of this Agreement. For this purpose an action is considered inconsistent with a representation if the
representation states that there is no plan or intention to take such action. In the event of a Distribution, [SUBSIDIARY] agrees that it will not take (and it will cause each [SUBSIDIARY] Affiliate to refrain from taking) any position on a Tax
Return that is inconsistent with such Distribution qualifying under Section 355 of the Code. 
 (b) Notwithstanding any other provision
of this Agreement for the period from the IPO Date until the date on which a Distribution is consummated (the “Pre-Distribution Period”), [SUBSIDIARY] shall not take any action (such action to include, without limitation, the
granting of restricted stock awards and the issuance of [SUBSIDIARY] stock (whether upon the exercise by the holders of any stock options or convertible securities issued by [SUBSIDIARY] or otherwise)) during the Pre-Distribution Period without the
prior written consent of BridgeBio if, as a result of such action, BridgeBio would or would reasonably be expected to cease to have Tax Control of [SUBSIDIARY] unless, prior to [SUBSIDIARY] taking such action BridgeBio has determined, in its sole
and absolute discretion, which discretion shall be exercised in good faith solely to preserve both BridgeBio’s Tax Control of [SUBSIDIARY] and the Tax Free Status of the Distribution, that such action will not jeopardize either BridgeBio’s
Tax Control of [SUBSIDIARY] or the Tax Free Status of the Distribution. In furtherance of the foregoing provisions of this Section 8.4(b), [SUBSIDIARY] shall be permitted to grant stock options and restricted stock awards to its employees which
have been approved by the compensation committee of the board of directors of [SUBSIDIARY] only so long as (i) [SUBSIDIARY] repurchases in the open market sufficient shares of issued and outstanding [SUBSIDIARY] stock prior to the date

  
 15 

 
such stock options are exercised or become transferable or such restricted stock awards are granted (or deemed granted) to ensure that BridgeBio will not cease to have Tax Control of [SUBSIDIARY]
at any time during the Pre-Distribution Period, (ii) [SUBSIDIARY] provides BridgeBio with prior written notification of the procedures taken by [SUBSIDIARY] to comply with its obligations described in clause (i) above, including
substantiation that the appropriate number of [SUBSIDIARY] shares have been repurchased, and (iii) BridgeBio approves of such procedures in writing (which approval shall not be unreasonably withheld). All of the restrictions on [SUBSIDIARY]
contained in this Section 8.4(b) shall apply to [SUBSIDIARY] to the extent that BridgeBio has “control” of [SUBSIDIARY] within the meaning of Section 368(c) of the Code and during the Pre-Distribution Period from and after the
time that BridgeBio notifies [SUBSIDIARY] of its intent to potentially effectuate a Distribution. In furtherance of [SUBSIDIARY]’s covenants under this Section 8.4(b), [SUBSIDIARY] shall instruct the [SUBSIDIARY] Transfer Agent not to
issue or deliver certificates representing, or other evidence of ownership of, newly issued shares of [SUBSIDIARY] stock during the Pre-Distribution Period without the prior written consent of BridgeBio. [SUBSIDIARY] hereby agrees that during the
Pre-Distribution Period, (a) BridgeBio will administer or oversee the administration of all issuances of shares of [SUBSIDIARY] stock (whether pursuant to stock options exercises, the granting of restricted stock awards, or otherwise) to ensure
that BridgeBio will not fail to have Tax Control of [SUBSIDIARY] at any time during the Pre-Distribution Period and (b) all grants of options, restricted stock awards and other issuances of similar instruments by [SUBSIDIARY] during the
Pre-Distribution Period shall include provisions to the effect that the grant or exercise of such option, award or other instrument shall be void AB INITIO if the effect of such grant or exercise (whether alone or when aggregated with other
issuances of [SUBSIDIARY] stock) would cause or would reasonably be expected to cause BridgeBio to fail to have Tax Control of [SUBSIDIARY] at any time during the Pre-Distribution Period. For the avoidance of doubt, [SUBSIDIARY] shall not be
required to take any action pursuant to this Section 8.4(b) if (1) such action would require the approval of the board of directors of [SUBSIDIARY], (2) [SUBSIDIARY] promptly undertakes to obtain such approval and (3) such
approval is not granted. 
 8.5 BridgeBio Distribution Restrictions. In the event of a Distribution, BridgeBio agrees that it will not take or fail to
take, or permit any BridgeBio Affiliate to take or fail to take, any action where such action or failure to act would be inconsistent with any material, information, covenant or representation that relates to facts or matters related to BridgeBio
(or any BridgeBio Affiliate) or within the control of BridgeBio and is contained in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents, Supplemental Ruling Documents, Ruling, or Supplemental Ruling. For this
purpose an action is considered inconsistent with a representation if the representation states that there is no plan or intention to take such action. In the event of a Distribution, BridgeBio agrees that it will not take (and it will cause each
BridgeBio Affiliate to refrain from taking) any position on a Tax Return that is inconsistent with such Distribution qualifying under Section 355 of the Code. 

8.6 Certain [SUBSIDIARY] Actions Following a Distribution. In the event of a Distribution, [SUBSIDIARY] agrees that, during the two (2) year period
following a Distribution, without first obtaining, at [SUBSIDIARY]’s own expense, either a supplemental opinion from Tax Counsel that such action will not result in Distribution Taxes (a “Supplemental Tax Opinion”) or a
Supplemental Ruling that such action will not result in Distribution Taxes, unless in any such case BridgeBio and [SUBSIDIARY] agree otherwise, [SUBSIDIARY] shall not (a) sell all or substantially all of the assets of [SUBSIDIARY] or any
[SUBSIDIARY] Affiliate, (b) merge [SUBSIDIARY] or any [SUBSIDIARY] Affiliate with another entity, without regard to which Party is the surviving entity, (c) transfer any assets of [SUBSIDIARY] in a transaction described in Section 351
(other than a transfer to a corporation which files a Consolidated Return with [SUBSIDIARY] and which is wholly-owned, directly or indirectly, by [SUBSIDIARY]) or subparagraph (C) or (D) of Section 368(a)(1) of the Code,
(d) issue stock of [SUBSIDIARY] or any 

  
 16 

 
[SUBSIDIARY] Affiliate (or any instrument that is convertible or exchangeable into any such stock) in an acquisition or public or private offering (other than any compensatory related issuances
as described in Treasury Regulation Section 1.355-7(e)(i)), or (e) facilitate or otherwise participate in any acquisition of stock in [SUBSIDIARY] that would result in any shareholder owning five percent (5%) or more of the
outstanding stock of [SUBSIDIARY]. [SUBSIDIARY] (or any [SUBSIDIARY] Affiliate) shall only undertake any of such actions after BridgeBio’s receipt of such Supplemental Tax Opinion or Supplemental Ruling and pursuant to the terms and conditions
of any such Supplemental Tax Opinion or Supplemental Ruling or as otherwise consented to in writing in advance by BridgeBio. The Parties hereby agree that they will act in good faith to take all reasonable steps necessary to amend this
Section 8.6, from time to time, by mutual agreement, to (i) add certain actions to the list contained herein, or (ii) remove certain actions from the list contained herein, in either case, in order to reflect any relevant change in
law, regulation or administrative interpretation occurring after the date of this Agreement. 
 8.7 Notice of Specified Transactions. Not later than
twenty (20) days prior to entering into any oral or written contract or agreement, and not later than twenty (20) days after it first becomes aware of any negotiations, plan or intention (regardless of whether it is a party to such
negotiations, plan or intention), regarding any of the transactions described in Section 8.6, [SUBSIDIARY] shall provide written notice of its intent to consummate such transaction or the negotiations, plan or intention of which it becomes
aware, as the case may be, to BridgeBio. 
 8.8 [SUBSIDIARY] Cooperation. [SUBSIDIARY] agrees that, at the request of BridgeBio, [SUBSIDIARY] shall
cooperate fully with BridgeBio to take any action necessary or reasonably helpful to effectuate a Distribution, including seeking to obtain, as expeditiously as possible, a Tax Opinion, Supplemental Tax Opinion, Ruling, and/or Supplemental Ruling.
Such cooperation shall include the execution of any documents that may be necessary or reasonably helpful in connection with obtaining any Tax Opinion, Supplemental Tax Opinion, Ruling, and/or Supplemental Ruling (including any (i) power of
attorney, (ii) Officer’s Certificate, (iii) Ruling Documents, (iv) Supplemental Ruling Documents, and/or (v) reasonably requested written representations confirming that (a) [SUBSIDIARY] has read the Officer’s
Certificate, Ruling Documents, and/or Supplemental Ruling Documents and (b) all information and representations, if any, relating to [SUBSIDIARY], any [SUBSIDIARY] Affiliate or the [SUBSIDIARY] Business contained therein are true, correct and
complete in all material respects). 
 8.9 Earnings and Profits. BridgeBio will advise [SUBSIDIARY] in writing of any decrease in BridgeBio earnings
and profits attributable to a Distribution under Section 312(h) of the Code on or before the first anniversary of a Distribution; provided, however, that BridgeBio shall provide [SUBSIDIARY] with estimates of such amounts
(determined in accordance with past practice) prior to such anniversary as reasonably requested by [SUBSIDIARY]. 
 Section 9.
Tax Proceedings 
 9.1 In General. Except as otherwise provided in this Agreement, (i) with respect to Tax Returns described in
Section 3.2 of this Agreement, BridgeBio and (ii) with respect to Tax Returns described in Section 3.3 of this Agreement, [SUBSIDIARY] (in either case, the “Controlling Party”), shall have the exclusive right, in its
sole discretion, to control, contest, and represent the interests of BridgeBio, any BridgeBio Affiliate, [SUBSIDIARY], and/or any [SUBSIDIARY] Affiliate in any Audit relating to such Tax Return and to resolve, settle or agree to any deficiency,
claim or adjustment proposed, asserted or assessed in connection with or as a result of any such Audit; provided that BridgeBio shall have the ability to elect to be treated as the Controlling Party for an Audit for which [SUBSIDIARY] would
otherwise be the Controlling Party. The Controlling Party’s rights shall extend to any matter pertaining to the management and control of an Audit, including execution of waivers, choice of forum, scheduling of conferences and the resolution of
any Tax Item. Any costs incurred in handling, settling, or contesting an Audit shall be borne by the Controlling Party. 

  
 17 

 9.2 Participation of non-Controlling Party. Except as otherwise provided in Section 9.4 of this
Agreement, the non-Controlling Party shall have control over decisions to resolve, settle or otherwise agree to any deficiency, claim or adjustment with respect to any Sole Responsibility Item. Except as otherwise provided in Section 9.4 of
this Agreement, the Controlling Party shall not settle any Audit it controls concerning a Tax Item on a basis that would reasonably be expected to adversely affect the non-Controlling Party by at least one hundred thousand dollars ($100,000) without
obtaining such non-Controlling Party’s consent, which consent shall not be unreasonably withheld, conditioned or delayed if failure to consent would adversely affect the Controlling Party. 

9.3 Notice. Within ten (10) business days after a Party becomes aware of the existence of a Tax issue that may give rise to an indemnification
obligation under this Agreement, such Party shall give prompt notice to the other Party of such issue (such notice shall contain factual information, to the extent known, describing any asserted Tax liability in reasonable detail), and shall
promptly forward to the other Party copies of all notices and material communications with any Taxing Authority relating to such issue. Notwithstanding any provision in Section 10.11 of this Agreement to the contrary, if a Party to this
Agreement fails to provide the other Party notice as required by this Section 9.3, and the failure results in a material detriment to the other Party, then any amount which the other Party is otherwise required to pay pursuant to this Agreement
shall be reduced by the amount of such detriment. 
 9.4 Control of Distribution Tax Proceedings. In the event of a Distribution, BridgeBio shall have
the exclusive right, in its sole discretion, to control, contest, and represent the interests of BridgeBio, any BridgeBio Affiliate, [SUBSIDIARY], and/or any [SUBSIDIARY] Affiliate in any Audits relating to Distribution Taxes and to resolve, settle
or agree to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of any such Audit; provided, however, that BridgeBio shall not settle any such Audit with respect to Distribution Taxes
with a Taxing Authority that would reasonably be expected to result in a material Tax cost to [SUBSIDIARY] or any [SUBSIDIARY] Affiliate, without the prior consent of [SUBSIDIARY], which consent shall not be unreasonably withheld, conditioned or
delayed. BridgeBio’s rights shall extend to any matter pertaining to the management and control of such Audit, including execution of waivers, choice of forum, scheduling of conferences and the resolution of any Tax Item; provided,
however, that to the extent that [SUBSIDIARY] is obligated to bear at least fifty percent (50%) of the liability for any Distribution Taxes under Section 8 of this Agreement, BridgeBio and [SUBSIDIARY] shall have joint control over
decisions to resolve, settle or otherwise agree to any deficiency, claim or adjustment. [SUBSIDIARY] may assume sole control of any Audits relating to Distribution Taxes if it acknowledges in writing that it has sole liability for any Distribution
Taxes under Section 8 of this Agreement that might arise in such Audit and can demonstrate to the reasonable satisfaction of BridgeBio that it can satisfy its liability for any such Distribution Taxes. If [SUBSIDIARY] is unable to demonstrate
to the reasonable satisfaction of BridgeBio that it will be able to satisfy its liability for such Distribution Taxes, but acknowledges in writing that it has sole liability for any Distribution Taxes under Section 8 of this Agreement,
[SUBSIDIARY] and BridgeBio shall have joint control over the Audit. 
 9.5 Post-Deconsolidation Tax Proceedings. In the event of any Audit after a
Deconsolidation Event of [SUBSIDIARY] or any [SUBSIDIARY] Affiliate, [SUBSIDIARY] or the [SUBSIDIARY] Affiliate shall not settle any portion of the Audit concerning a Tax Item that could impact any Tax position, Tax liability or Tax Asset that was
reported, or will be reportable, on any Consolidated Return or Combined Return without obtaining BridgeBio’s consent, which consent shall not be unreasonably withheld, conditioned or delayed. 

  
 18 

 Section 10. Miscellaneous Provisions 

10.1 Additional Members. If future subsidiaries are acquired or created and they participate in the Consolidated Return or Combined Return, such
subsidiaries may join in and be bound by this Agreement. This section will also apply to subsidiaries that are not eligible immediately to join the Affiliated Group, when they become eligible to join the Affiliated Group. Admission to the Affiliated
Group shall be determined by BridgeBio in its sole and exclusive discretion. 
 10.2 Counterparts. This Agreement may be executed in counterparts,
each of which shall constitute an original and all of which, when taken together, shall constitute one Agreement. 
 10.3 Disputes. In the event of a
disagreement between any of BridgeBio, a BridgeBio Affiliate, [SUBSIDIARY] and a [SUBSIDIARY] Affiliate with respect to any determination required to be made pursuant to this Agreement, the Parties shall attempt in good faith to resolve such
dispute. If such dispute is not resolved within sixty (60) business days following the commencement of the dispute, BridgeBio and [SUBSIDIARY] shall jointly retain the Independent Accountant. The Independent Accountant shall act as an
arbitrator to resolve all points of disagreement and its decision shall be final and binding upon all Parties involved. Following the decision of the Independent Accountant, BridgeBio and [SUBSIDIARY] shall each take or cause to be taken any action
necessary to implement the decision of the Independent Accountant. The fees and expenses relating to the Independent Accountant shall be borne equally by BridgeBio and [SUBSIDIARY], except that if the Independent Accountant determines that the
position advanced by either Party is frivolous, has not been asserted in good faith or for which there is not “substantial authority”, one hundred percent (100%) of the fees and expenses of the Independent Accountant shall be borne by
such Party. Notwithstanding anything in this Agreement to the contrary, the dispute resolution provisions set forth in this Section 10.3 shall not be applicable to any disagreement between the Parties relating to Distribution Taxes and any such
dispute shall be settled in a court of law or as otherwise agreed to by the Parties. 
 10.4 Amendment. This Agreement may be amended, modified,
superseded, cancelled or extended, and the provisions hereof may be waived, only by a written instrument signed by the Parties or, in the case of a waiver, by the Party waiving compliance. 

10.5 Successors and Assigns. This Agreement shall be binding upon, and shall inure to all the benefits of, the Parties hereto and their respective
successors and assigns. 
 10.6 Binding Effect. This Agreement shall be binding on and inure to the benefit of any successor, by merger, acquisition
of assets or otherwise, to any of the Parties thereto to the same extent as if such successor had been an original Party to this Agreement; but no assignment shall relieve any Party’s obligations hereunder without the written consent of
BridgeBio. Although it is intended this Agreement have as signatories all Parties of the Affiliated Group, any omission shall not have any effect on the binding nature of this Agreement as to the signatories thereto. 

10.7 Entire Agreement. This Agreement constitutes the entire agreement among the Parties hereto with respect to the subject matter hereof and supersede
and terminate and any and all prior agreements and understanding, both written and oral. 
 10.8 Continuity of Agreement. 

(a) This Agreement shall be effective with respect to each Party thereto upon signing by such Party, and shall supersede any and all previous
agreements by and amongst BridgeBio, each BridgeBio Affiliate, [SUBSIDIARY] and each [SUBSIDIARY] Affiliate with respect to the matters contained herein and any such previous agreements shall thereupon terminate. 

  
 19 

 (b) Failure of one or more Parties hereto to qualify by meeting the definition of
[SUBSIDIARY] Affiliate or BridgeBio Affiliate shall not operate to terminate this Agreement with respect to the other Parties as long as two or more Parties hereto continue to so qualify. Any Party to this Agreement which leaves the Affiliated Group
shall continue to be bound by this Agreement with respect to any Taxable Periods (or portions thereof) for which it was a member of such Affiliated Group, unless determined otherwise by BridgeBio in its sole and exclusive discretion. 

10.9 Severability. In the event any one or more of the provisions contained in this Agreement should be invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the
remaining terms, provisions, covenants and restrictions hereof without including any of such which may hereafter be declared invalid, void or unenforceable. In the event that any such term, provision, covenant or restriction is hereafter held to be
invalid, void or unenforceable, the Parties hereto agree to use their best efforts to find and employ an alternate means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. 

10.10 Governing Law. This Agreement shall be governed by the laws of the State of Delaware, without regard to the conflict of laws rules thereof. 

10.11 Waivers. No failure or delay on the part of a Party in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power. No modification or
waiver of any provision of this Agreement nor consent to any departure by the Parties therefrom shall in any event be effective unless the same shall be in writing, and then such waiver or consent shall be effective only in the specific instance and
for the purpose for which given. 
 10.12 Setoff. All payments to be made by any Party under this Agreement may be netted against payments due to such
Party under this Agreement, but otherwise shall be made without setoff, counterclaim or withholding, all of which are hereby expressly waived. 
 10.13
Specific Performance. The Parties hereto acknowledge and agree that irreparable damages will result if this Agreement is not performed in accordance with its terms, and each Party agrees that any damages available at law for a breach of this
Agreement would not be an adequate remedy. Therefore, to the full extent permitted by applicable law, the provisions hereof and the obligations of the Parties hereunder shall be enforceable in a court of equity, or other tribunal with jurisdiction,
by a decree of specific performance, and appropriate injunctive relief may be applied for and granted in connection therewith. 
 10.14 Notices. Any
notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, telegraphed, sent by facsimile transmission or sent by certified, registered or overnight express mail, postage prepaid. Any such
notice shall be deemed given when so delivered personally, telegraphed, telexed or sent by facsimile transmission or, if mailed by overnight mail, the day after the date of deposit with a reputable courier service, or if mailed by non-overnight
certified or registered mail, five (5) days after the date of deposit in the United States mails, as follows: 

  
 20 

	 	(A)	 If to BridgeBio or a BridgeBio Affiliate: 

BridgeBio Pharma, Inc. 

421 Kipling Street 

Palo Alto, California 94301 

Attention: Chief Financial Officer 
  

	 	(B)	 If to [SUBSIDIARY] or a [SUBSIDIARY] Affiliate: 

[SUBSIDIARY] 

[ADDRESS] 

Attention: [OFFICER] 

Any Party may by notice given in accordance with this Section to the other Parties designate another address or person for receipt of notices
hereunder. 
 [Signature Page Follows] 

  
 21 

 IN WITNESS WHEREOF, BridgeBio, each BridgeBio Affiliate, [SUBSIDIARY], and each [SUBSIDIARY] Affiliate has
executed this Agreement as of the day and year first above written. 
  

			
	By: BridgeBio Pharma, Inc.
	on behalf of itself and each of the BridgeBio Affiliates
		
	        By:	 	 

                          
      

	        Name:
	        Title: Authorized Signatory
	
	 By: [SUBSIDIARY]
 on behalf of
itself and each of the [SUBSIDIARY] Affiliates

		
	        By:	 	 
	        Name:
	        Title: Authorized Signatory

 [Signature page to Tax Sharing Agreement] 

  
 22EX-10.28

 Exhibit 10.28 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (this “Agreement”) is entered into as of the 26th day of March, 2016 by BridgeBio
Pharma LLC, a Delaware limited liability company (including any successor thereof) (the “Company”), for the benefit of KKR Genetic Disorder L.P., a Delaware limited partnership (“KKR”) and its Affiliates (each, an
“Indemnitee” and collectively, the “Indemnitees”). 
 NOW
THEREFORE, the Company and each Indemnitee hereby agrees as follows: 

1.    Indemnification. 

(a)    Indemnification of Expenses. The Company shall indemnify and hold harmless each Indemnitee and their
respective directors, managers, officers, general partners, limited partners, members, managing members, employees, agents, advisors, consultants, representatives and each person who controls any Indemnitee under applicable principles of state law
regarding vicarious liability (including principles of respondent superior), or who may be liable within the meaning of Section 15 of the Securities Act of 1933, as amended (the “Securities Act”), or Section 20 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), in each case irrespective of the capacity in which such Person acts, to the fullest extent permitted by law if such Indemnitee was or is or becomes a party to or
witness or other participant in, or is threatened to be made a party to or witness or other participant in, any threatened, pending or completed action, suit, proceeding or alternative dispute resolution mechanism, or any hearing, inquiry or
investigation that would reasonably be expected to result in the institution of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, regulatory, investigative or other (hereinafter a
“Claim”) by reason of (or arising in part out of or in connection with) any event or occurrence related to the fact that Indemnitee is or was or may be deemed a director, manager, officer, Member, employee, controlling person, agent
or fiduciary of the Company, or any subsidiary of the Company, or is or was serving at the request of the Company as a director, manager, officer, Member, employee, controlling person, agent or fiduciary of another limited liability company,
corporation, partnership, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of such Indemnitee while serving in such capacity, including any and all losses, claims, damages (including punitive and exemplary
damages), obligations, penalties, fines, fees, expenses and liabilities, joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement of, any action, suit, proceeding or any
claim asserted), (i) under the Securities Act, the Exchange Act, the Investment Adviser Act, the Investment Company Act or other federal or state statutory law or regulation, at common law or otherwise, which relate directly or indirectly to the
registration, purchase, sale or ownership of any securities of the Company, (ii) in connection with any fiduciary obligation owed by an Indemnitee with respect thereto or (iii) as a result of any claim (A) against an Indemnitee and
arising out of or related to any round of financing of the Company (including claims regarding participation, non-participation, or non-prorata participation, in such
round by such Member or by Indemnitee or any Affiliate or related entity), or by reason of any actions or omissions or alleged acts or omissions arising out of such Indemnitee’s activities either on behalf of the Company or in furtherance of
the interests of the Company or arising out of or in connection with its purchase or ownership of equity interests in the Company or its involvement 

 
in the transactions contemplated by the definitive agreements with respect to any round of financing of the Company, (B) made by a third party against an Indemnitee based on any misstatement
or omission of a material fact by the Company in violation of any duty of disclosure imposed on the Company by Federal or state securities or common laws, (C) made by a third party against an Indemnitee based (in whole or in part) on, or
arising in any way out of, or relating to (1) the Indemnitee being an investor in the Company, (2) the Indemnitee’s alleged participation in the management or direction of the Company, (3) the Indemnitee’s alleged
participation in providing any assistance or advice to the Company, (4) Indemnitee being a person described in Section 15 of Securities Act or Section 20 of the Exchange Act, or (5) related to the status of the Company or its
Affiliates as an investment adviser under the Investment Adviser Act or as an investment company under the under the Investment Company Act or (D) related to a breach of the LLC Agreement or Purchase Agreement by the Company (hereinafter an
individually an “Indemnification Event” and collectively the “Indemnification Events”) against any and all expenses (including reasonable attorney’s fees and all other out-of-pockets costs, expenses and obligations reasonably incurred in connection with prosecuting, investigating, defending, being a witness in or participating in (including an appeal), or preparing to
prosecute or defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution mechanism, hearing, inquiry or investigation), judgments, fines, penalties and amounts paid in settlement (if, and only if,
such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) of such Claim and any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments
under this Agreement, including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses (collectively, hereinafter “Expenses”). Such payment of Expenses shall be made by the
Company as soon as practicable but in any event no later than thirty (30) days after receipt by the Company of a statement or statements from Indemnitee requesting such payment(s) or advance(s) from time to time, whether prior to or after final
disposition of such Claim. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and, to the extent that such payment is an Expense Advance (as defined below), shall include or be preceded or accompanied by a
written undertaking by or on behalf of Indemnitee to repay any such Expense Advance if the Company is entitled to be reimbursed by Indemnitee for such Expense Advance pursuant to the terms of Section 2(b). 

(b)    Reviewing Party. Notwithstanding the foregoing, (i) the obligations of the Company under
Section 1(a) shall be subject to the condition that it shall not have been finally judicially determined with respect thereto that Indemnitee would not be permitted to be indemnified under applicable law, and (ii) and each Indemnitee
acknowledges and agrees that the obligation of the Company to make an advance payment of Expenses to Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall be subject to the condition that, if, when and to the extent
that it is so determined that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore
paid; provided, however, that if Indemnitee has commenced or thereafter commences legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified under applicable law, any initial determination
made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial

  
 2 

 
determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s obligation to reimburse the Company for any Expense
Advance shall be unsecured and no interest shall be charged thereon. If there has not been a Change in Control (as defined in Section 9(c) hereof), the Reviewing Party shall be selected by the Manager (as defined in the LLC Agreement), and if
there has been such a Change in Control (other than a Change in Control which has been approved by the Manager), the Reviewing Party shall be the Independent Legal Counsel referred to in Section 1(e) hereof. If there has been no determination
by the Reviewing Party or if the Reviewing Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law, Indemnitee shall have the right to commence litigation seeking an initial
determination by the court or challenging any such determination by the Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company hereby consents to service of process and to appear in any such proceeding.
Any determination by the Reviewing Party otherwise shall be conclusive and binding on the Company and Indemnitee. 

(c)    Contribution. If the indemnification provided for in Section 1(a) above for any reason is held
by a court of competent jurisdiction to be unavailable to an Indemnitee in respect of any Expenses referred to therein, then the Company, in lieu of indemnifying such Indemnitee thereunder, shall contribute to the amount paid or payable by such
Indemnitee as a result of such Expenses (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Indemnitee, or (ii) if the allocation provided by clause (i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company and the Indemnitee in connection with the action or inaction which
resulted in such Expenses, as well as any other relevant equitable considerations which applicable law may require to be considered. In connection with the registration of the Company’s securities, the relative benefits received by the Company
and the Indemnitee shall be deemed to be in the same respective proportions that the net proceeds from the offering (before deducting expenses) received by the Company and the Indemnitee, in each case as set forth in the table on the cover page of
the applicable prospectus, bear to the aggregate public offering price of the securities so offered. The relative fault of the Company and the Indemnitee shall be determined by reference to, among other things, applicable law, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Indemnitee and the parties relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. 
 The Company and the Indemnitee agree that it would not be just and
equitable if contribution pursuant to this Section 1(c) were determined by pro rata or per capita allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding paragraph. In connection with the registration of the Company’s securities, in no event shall Indemnitee be required to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the
total of such Expenses indemnified against equal to the proportion of the total securities sold under such registration statement which is being sold by such Indemnitee or (ii) the proceeds received by such Indemnitee from its sale of
securities under such registration statement. No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such
fraudulent misrepresentation. 

  
 3 

 (d)    Survival Regardless of Investigation. The
indemnification and contribution provided for in this Section 1 will remain in full force and effect regardless of any investigation made by or on behalf of the Indemnitee or any officer, director, manager, general partner, limited partner,
member, managing member, employee, agent or controlling person of the Indemnitee. 
 (e)    Change in
Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has been approved by the Manager) then, with respect to all matters thereafter arising concerning the rights of Indemnitee to
payments of Expenses under this Agreement or any other agreement or under the LLC Agreement, Independent Legal Counsel (as defined in Section 9(d) hereof) shall be selected by the Indemnitee and approved by the Company (which approval shall not
be unreasonably withheld). Such counsel, among other things, shall render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to
abide by such opinion and to pay the reasonable fees of the Independent Legal Counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorney’s fees), claims, liabilities and damages (including
punitive and exemplary damages) arising out of or relating to this Agreement or its engagement pursuant hereto. 

(f)    Mandatory Payment of Expenses. Notwithstanding any other provision of this Agreement, but subject to
Section 7 below, to the extent that Indemnitee has been successful on the merits or otherwise, including the dismissal of an action without prejudice, in the defense of any action, suit, proceeding, inquiry or investigation referred to in
Section 1(a) hereof or in the defense of any claim, issue or matter therein, each Indemnitee shall be indemnified against all Expenses incurred by such Indemnitee in connection herewith. 

2.    Expenses; Indemnification Procedure. 

(a)    Notice/Cooperation by Indemnitee. Indemnitee shall notify the Company in writing upon being served
with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Claim or matter which may be subject to indemnification covered hereunder. Notice to the Company shall be directed to
the Manager at the address shown on the signature page of this Agreement (or such other address as the Company shall designate in writing to Indemnitee). Failure to provide notice in accordance with this Section 2(a) shall not relieve the
Company of any of its obligations under the Agreement. 
 (b)    No Presumptions; Burden of Proof. For
purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that
Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to have made a
determination as to 

  
 4 

 
whether Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct
or did not have such belief, prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified under applicable law, shall be a defense to Indemnitee’s claim or create a
presumption that Indemnitee has not met any particular standard of conduct or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified
hereunder, the burden of proof shall be on the Company to establish that Indemnitee is not so entitled. 

(c)    Notice to Insurers. If, at the time of the receipt by the Company of a notice of a Claim pursuant to
Section 2(b) hereof, the Company has liability insurance in effect which may cover such Claim, the Company may, in its sole discretion, give prompt written notice of the commencement of such Claim to the insurers in accordance with the
procedures set forth in each of the policies. 
 (d)    Selection of Counsel. In the event the Company may
be obligated hereunder to pay the Expenses of any Claim, the Company shall be entitled to assume the defense of such Claim upon the delivery to such Indemnitee of written notice of its election to do so; provided that, (i) the Company
acknowledges in such written notice that it has an obligation under this Agreement to indemnify such Indemnitee with respect to such Claim and (ii) the Company is represented at all times by counsel from a nationally recognized law firm with
respect to such Claim. After delivery of such notice and the retention of such counsel by the Company, the Company will not be liable to such Indemnitee under this Agreement for any fees of counsel subsequently incurred by such Indemnitee with
respect to the same Claim; provided that, (i) the Indemnitee shall have the right to employ Indemnitee’s own counsel in any such Claim at the Indemnitee’s expense; (ii) the Indemnitee shall have the right to employ
Indemnitee’s own counsel in connection with any such proceeding, at the expense of the Company, if such counsel serves in a review, observer, advice and counseling capacity and does not otherwise materially control or participate in the defense
of such proceeding; and (iii) if either (A) the employment of counsel by the Indemnitee has been previously authorized by the Company, (B) such Indemnitee shall have reasonably concluded that there is a conflict of interest between
the Company and such Indemnitee in the conduct of any such defense, or (C) the Company shall not continue to retain such counsel to defend such Claim, then the fees and expenses of the Indemnitee’s counsel shall be at the expense of the
Company. 
 3.    Additional Indemnification Rights; Nonexclusivity. 

(a)    Scope. The Company hereby agrees to indemnify each Indemnitee to the fullest extent permitted by law,
even if such indemnification is not specifically authorized by the other provisions of this Agreement or any other agreement, the LLC Agreement or by statute. The Company and each Indemnitee acknowledge that in certain instances, Federal law or
applicable public policy may prohibit the Company from indemnifying its managers, officers, Member, employees, controlling persons, agents or fiduciaries under this Agreement or otherwise. 

  
 5 

 (b)    Nonexclusivity. The indemnification provided by
this Agreement shall be in addition to any rights to which each Indemnitee may be entitled under the LLC Agreement, any agreement, any vote of Members or disinterested managers, the laws of the State of California or the State of Delaware, or
otherwise. The indemnification provided under this Agreement shall continue as to each Indemnitee for any action such Indemnitee took or did not take while serving in an indemnified capacity even though the Indemnitee may have ceased to serve in
such capacity. 
 4.    No Duplication of Payments. Subject to Section 10 below in all respects, the
Company shall not be liable under this Agreement to make any payment to any Indemnitee (whether in connection with any Claim made against any Indemnitee or otherwise) to the extent such Indemnitee has otherwise actually received payment from any
third party (under any insurance policy, the LLC Agreement or otherwise) of the amounts otherwise indemnifiable hereunder; provided, that if the Company makes a payment to an Indemnitee in connection with a Claim and such Indemnitee thereafter
actually receives payment from any third party (under any insurance policy, the LLC Agreement or otherwise) of amounts indemnifiable by the Company hereunder in connection with such Claim, the Company shall be entitled to be reimbursed by Indemnitee
(who hereby agrees to reimburse the Company) an amount equal to the lesser of (i) the amount of the payment from such third party and (ii) the amount of the payment made by the Company to the Indemnitee in connection with such Claim. 

5.    Partial Indemnification. If any Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for any portion of Expenses incurred in connection with any Claim, but not, however, for the entire total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses to which
such Indemnitee is entitled. 
 6.    Intentionally Omitted. 

7.    Exceptions. Notwithstanding any other provision herein to the contrary, the Company shall not be
obligated pursuant to the terms of this Agreement: 
 (a)    Claims Initiated by Indemnitee. To indemnify
or advance expenses to any Indemnitee with respect to Claims initiated or brought voluntarily by such Indemnitee and not by way of defense, except (i) with respect to actions or proceedings to establish or enforce a right to indemnification
under this Agreement or any other agreement relating to Claims for Indemnifiable Events or to establish or enforce a right to indemnification under applicable law in accordance with Section 16 or (ii) as otherwise required under applicable
state statute or law, regardless of whether such Indemnitee ultimately is determined to be entitled to such indemnification, advance expense payment or insurance recovery, as the case may be; 

(b)    Claim Under Section 16(b). To indemnify any Indemnitee for expenses and the
payment of profits arising from the purchase and sale by such Indemnitee of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute; 

  
 6 

 (c)    Willful Misconduct or Bad Faith. To indemnify or
advance expenses to any Indemnitee to the extent that any indemnifiable amounts arise out of or are related to any willful misconduct or bad faith on the part of such Indemnitee; or 

(d)    Unlawful Indemnification. To indemnify or advance expenses to an Indemnitee if a final decision by a
court having jurisdiction in the matter shall determine that such indemnification is not lawful. 

8.    Period of Limitations. No legal action shall be brought and no cause of action shall be asserted by or
in the right of the Company against any Indemnitee, any Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of accrual of such cause of action, and any
claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5) year period; provided, however, that if any shorter period of limitations is otherwise
applicable to any such cause of action, such shorter period shall govern. 
 9.    Construction of Certain
Phrases. For purposes of this Agreement, 
 (a)    “Affiliate” means, with reference to a
specified Person, a Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, the specified Person. The following Persons shall not be considered Affiliates of KKR or of any
of KKR’s Affiliates for purposes of this Agreement: (i) the Company and its Affiliates, (ii) any portfolio company of KKR or any of its Affiliates, and (iii) any of the Affiliates of such portfolio company. 

(b)    “Control” means (including as used in the terms “Controlling,” “Controlled
by” and “under common Control with”) means possession, directly or indirectly, of (a) more than 50% of the securities or other ownership interests in a Person or the voting power of a Person or (b) the power to direct or
cause the direction of management or policies of a Person (whether through ownership of voting securities, by agreement or otherwise). 

(c)    References to the “Company” shall include, in addition to the resulting entity, any
constituent entity (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its manager, officers, Members, employees,
consultants, advisors, agents or fiduciaries, so that if Indemnitee is or was or may be deemed a manager, officer, Member, employee, consultant, advisor, agent, control person, or fiduciary of such constituent entity, or is or was or may be deemed
to be serving at the request of such constituent entity as a manager, officer, Member, employee, consultant, advisor, control person, agent or fiduciary of another limited liability company, corporation, partnership, joint venture, employee benefit
plan, trust or other enterprise, each Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving entity as each Indemnitee would have with respect to such constituent entity if its
separate existence had continued. 
 (d)    References to “other enterprises” shall include
employee benefit plans; references to “fines” shall include any excise taxes assessed on any Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall

  
 7 

 
include any service as a manager, officer, Member, employee, agent or fiduciary of the Company which imposes duties on, or involves services by, such manager, officer, Member, employee, agent or
fiduciary with respect to an employee benefit plan, its participants or its beneficiaries; and if any Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of
an employee benefit plan, such Indemnitee shall be deemed to have acted in a manner not opposed to the best interests of the Company as referred to in this Agreement. 

(e)    A “Change in Control” shall be deemed to have occurred if (i) any person (as such term
is used in Section 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or an entity owned directly or indirectly by the Members of the Company in
substantially the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly or indirectly, of securities of the Company representing twenty five percent (25%) or more of the combined
voting power of the Company’s then outstanding Voting Securities, increases his beneficial ownership of such securities by ten percent (10%) or more over the percentage so owned by such person, or (B) becomes the beneficial owner (as
defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then
outstanding Voting Securities, (ii) after the closing of the initial public offering of the equity securities of the Company or any successor thereto (including pursuant to a conversion to a corporation), during any period of two
(2) consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Company and any new director whose election by the Board of Directors or combination for election by the Company’s stockholders
was approved by a vote of at least two-thirds (2/3) of the members of the Board of Directors then still in office who either were members of the Board of Directors at the beginning of the period or whose
election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof or (iii) the Members of the Company approve a merger or consolidation of the Company with any other entity other than a merger
or consolidation which would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least
two-thirds (2/3) of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the Members of the Company
approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all of the Company’s assets. 

(f)    “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in
accordance with the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company, any Indemnitee or any party to a Claim giving rise to a claim for indemnification hereunder within the last five
(5) years (other than with respect to matters concerning the right of any Indemnitee under this Agreement, or of other indemnitees under similar indemnity agreements). 

  
 8 

 (g)    “LLC Agreement” shall mean the Second
Amended and Restated Limited Liability Agreement of the Company, dated as of the date hereof, as amended and in effect from time to time. 

(h)    “Member” shall include any holder of any equity securities of the Company and an Affiliate
thereof. 
 (i)    “Person” shall mean any natural person or any corporation, partnership,
limited liability company, joint venture, trust or other entity. 
 (j)    “Purchase Agreement”
shall mean the Series B Preferred Unit Purchase Agreement, dated as of the date hereof, by and among the Company and the purchasers of Series B Preferred Units of the Company listed on the signature pages thereto. 

(k)    A “Reviewing Party” shall mean any appropriate person or body consisting of the Manager or
any other person or body appointed by the Manager who is not a party to the particular Claim for which Indemnitee is seeking indemnification or Independent Legal Counsel. 

(l)    “Voting Securities” shall mean any securities of the Company that vote generally in the
election of managers. 
 10.    Fund Indemnitors. Notwithstanding anything to the contrary set
forth herein, the rights, indemnities and remedies herein provided herein are cumulative and are not exclusive of any rights, indemnities or remedies that Indemnitee may otherwise have by contract, at law or in equity or otherwise and the Company
hereby acknowledges that Indemnitees have or may have in the future certain rights to indemnification, advancement of expenses and/or insurance provided by other entities and/or organizations (collectively, the “Fund Indemnitors”).
The Company hereby agrees (i) that it is the indemnitor of first resort with respect to any Claim under this Agreement (i.e., its obligations to each Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to
provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses,
judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the LLC Agreement (or any other agreement between the Company and Indemnitee), without regard to any rights
Indemnitee may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of
any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the
foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and each Indemnitee agree that
the Fund Indemnitors are express third party beneficiaries of the terms of this Section 10. 

  
 9 

 11.    Counterparts. This Agreement may be executed in one
or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in
counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be
produced to evidence the existence of this Agreement. 
 12.    Binding Effect; Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or
substantially all of the business and/or assets of the Company, partnership, spouses, heirs, and personal and legal representatives. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or
otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to each Indemnitee, expressly to assume and agree to perform this Agreement in the
same manner and to the same extent that the Company would be required to perform if no such succession had taken place (and, if the Company continues to exist following such transaction, the Company shall not be relieved of its obligations under
this Agreement, but shall remain liable hereunder, notwithstanding such assumption by such successor). This Agreement shall continue in effect with respect to Claims relating to Indemnifiable Events regardless of whether any Indemnitee continues to
serve as a manager, officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including subsidiaries of the Company, at the Company’s request. 

13.    Attorneys’ Fees. In the event that any action is instituted by an Indemnitee under this Agreement or
under any liability insurance policies maintained by the Company to enforce, assert or exercise any of its rights, powers, privileges or remedies in respect hereof or thereof or interpret any of the terms hereof or thereof, such Indemnitee shall be
entitled to be paid all Expenses incurred by such Indemnitee with respect to such action, regardless of whether such Indemnitee is ultimately successful in such action, and shall be entitled to the advancement of Expenses with respect to such
action, unless, as a part of such action, a court of competent jurisdiction over such action determines that each of the material assertions made by such Indemnitee as a basis for such action was not made in good faith or was frivolous. In the event
of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms of this Agreement, the Indemnitee shall be entitled to be paid all Expenses incurred by such Indemnitee in defense of such action
(including costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made in such action), and shall be entitled to the advancement of Expenses with respect to such action. 

  
 10 

 14.    Notice. All notices, requests, demands and other
communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by
certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have
been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: 
  

	 	(a)	 If to Indemnitee: 

			
	
	 KKR Genetic Disorder L.P.
 c/o
Kohlberg Kravis Roberts & Co. L.P.
 2800 Sand Hill Road, Suite 200

	Menlo Park, CA 94025
	Attention:	 	Ali J. Satvat
	 Email: Ali.Satvat@kkr.com
  

with a copy (which shall not constitute notice):

	
	 Latham & Watkins LLP
 140
Scott Drive

	Menlo Park, CA 94025
	Attention:	 	Josh Dubofsky
		 	Ben Potter

 
			
	Email:	 	 josh.dubofsky@lw.com

benjamin.potter@lw.com

 or to any other address as may have been furnished to the Company by the Indemnitee. 

 

	 	(b)	 If to the Company to 

			
	
	 BridgeBio Pharma LLC
 7 Sandstone
Street

	Portola Valley, California 94028,
	Attention: Neil Kumar
	 E-mail: nkumar@bridgebiocapital.com

 
 with a copy (which shall not constitute notice):

	
	Proskauer Rose LLP
	One International Place
	Boston, MA 02110,
	Attention:	 	Ori Solomon, Esq.
		 	Michael Suppappola, Esq.

 
			
	Email:	 	osolomon@proskauer.com
		 	msuppappola@proskauer.com

 or to any other address as may have been furnished to Indemnitee by the Company. 

  
 11 

 15.    Severability. If any provision or provisions of
this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including each portion of any Section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
applicable law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the
provisions of this Agreement (including each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give
effect to the intent manifested thereby. 
 16.    Applicable Law and Consent to Jurisdiction. This
Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules that could require the application of any other
laws. The Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware and any
state appellate court therefrom within the State of Delaware (unless the Chancery Court declines to accept jurisdiction over a particular matter, in which case, in any Delaware state or federal court within the State of Delaware) (the
“Chosen Courts”), and not in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Chosen Courts for purposes of any
action or proceeding arising out of or in connection with this Agreement, (c) waive any objection to the laying of venue of any such action or proceeding in the Chosen Courts, and (d) waive, and agree not to plead or to make, any claim
that any such action or proceeding brought in the Chosen Courts has been brought in an improper or inconvenient forum 

17.    Amendment and Termination. No amendment, modification, termination or cancellation of this Agreement
shall be effective unless it is in writing signed by the parties to be bound thereby. Notice of same shall be provided to all parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

18.    No Construction as Employment Agreement. Nothing contained in this Agreement shall be construed as
giving any Indemnitee any right to be retained in the employ of the Company or any of its subsidiaries. 

19.    Corporate Authority. The Manager has approved the terms of this Agreement in accordance with Delaware
law. 
 20.    Miscellaneous. 

(a)    Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The
headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 

  
 12 

 (b)    The words “hereof,” “herein” and
“hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(c)    The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 
 (d)    Any singular term in this Agreement shall be deemed to
include the plural, and any plural term the singular, and words denoting either gender shall include both genders as the context requires. Where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding
meaning. 
 (e)    Whenever the words “include,” “includes” or “including” are used
in this Agreement, they shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like import. 

(f)    The use of the word “or” shall not be inclusive. 

[SPACE INTENTIONALLY LEFT BLANK] 

  
 13 

 IN WITNESS WHEREOF, the
Company hereby agrees and executes this Agreement on and as of the day and year first above written, and by physical acceptance and without need of signature the Indemnitees hereby agree to and accept this Agreement. 

 

			
	 COMPANY
  

	 BridgeBio Pharma LLC,

a Delaware limited liability company
  

	 By: Neil Kumar, LLC, its Manager

		
	 By:
	 	  

	 Name:
	 	Neil Kumar
	 Title:
	 	Sole Member

  

			
	Address:	 	7 Sandstone Street
		 	Portola Valley, CA 94028
		 	Attn: Neil Kumar
		 	E-mail: nkumar@bridgebiocapital.com

  

			
	 INDEMNITEE
  

	KKR Genetic Disorder L.P., a Delaware limited
partnership

  

			
	Address:	 	c/o Kohlberg Kravis Roberts & Co. L.P.
		 	2800 Sand Hill Road, Suite 200
		 	Menlo Park, CA 94025
		 	Attention: Ali J. Satvat

  
 [Signature Page to
Indemnification Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]